The year in non ST-segment elevation acute coronary syndrome

Journal of the American College of Cardiology

Volumn 58, Issue 22, 2011, Pages 2342-2354

  Giugliano, Robert P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndrome(s); myocardial infarction; unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ADRENOMEDULLIN; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; ARYLDIALKYLPHOSPHATASE 1; ATOPAXAR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 9A; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOPIDOGREL; CYTOCHROME P450 2C19; EVEROLIMUS; FONDAPARINUX; GELATINASE B; HEPARIN; HIGH DENSITY LIPOPROTEIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; TROPONIN; VORAPAXAR; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; BARE METAL STENT; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CYP2C19 GENE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; GENE; GENOTYPE; HEALTH CARE QUALITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORTALITY; MUSCLE DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RISK ASSESSMENT; SINGLE DRUG DOSE; STENT THROMBOSIS; STROKE; SUDDEN DEATH; VASCULAR ACCESS;

EID: 81255167006     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.08.042     Document Type: Review

References (101)

1. P.A. Heidenreich, J.G. Trogdon, and O.A. Khavjou Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
2. R.W. Yeh, S. Sidney, M. Chandra, M. Sorel, J.V. Selby, and A.S. Go Population trends in the incidence and outcomes of acute myocardial infarction N Engl J Med 362 2010 2155 2165
3. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 e215 e367
4. C.W. Hamm, J.P. Bassand, and S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 2011 Sep 21 [E-pub ahead of print]
5. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 56 2010 2051 2066
6. Y. Ino, T. Kubo, and A. Tanaka Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study JACC Cardiovasc Interv 4 2011 76 82
7. M. Mizukoshi, T. Imanishi, and A. Tanaka Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris Am J Cardiol 106 2010 323 328
8. G.W. Stone, A. Maehara, and A.J. Lansky A prospective natural-history study of coronary atherosclerosis N Engl J Med 364 2011 226 235
9. D. Vancraeynest, A. Pasquet, V. Roelants, B.L. Gerber, and J.L. Vanoverschelde Imaging the vulnerable plaque J Am Coll Cardiol 57 2011 1961 1979
10. P. Ong, A. Athanasiadis, G. Borgulya, M. Voehringer, and U. Sechtem 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (Coronary Artery Spasm in Patients with Acute Coronary Syndrome) study follow-up J Am Coll Cardiol 57 2011 147 152
11. D.A. Morrow Cardiovascular risk prediction in patients with stable and unstable coronary heart disease Circulation 121 2010 2681 2691
12. T.S. Nawrot, L. Perez, N. Kunzli, E. Munters, and B. Nemery Public health importance of triggers of myocardial infarction: a comparative risk assessment Lancet 377 2011 732 740
13. R.D. Brook, S. Rajagopalan, and C.A. Pope 3rd Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association Circulation 121 2010 2331 2378
14. B.J. Gersh, K. Sliwa, B.M. Mayosi, and S. Yusuf Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications Eur Heart J 31 2010 642 648
15. E.M. Antman, M. Cohen, and P.J. Bernink The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842 (Pubitemid 30643610)
16. M. Than, L. Cullen, and C.M. Reid A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study Lancet 377 2011 1077 1084
17. B.M. Scirica, E. Braunwald, and L. Belardinelli Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 122 2010 455 462
18. W. Whang, D. Shimbo, and I.M. Kronish Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]) Am J Cardiol 106 2010 1104 1107
19. F. Boccara, M. Mary-Krause, and E. Teiger Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis Eur Heart J 32 2011 41 50
20. M.J. Pletcher, and M. Pignone Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact Circulation 123 2011 1116 1124
21. N.L. Mills, A.M. Churchhouse, and K.K. Lee Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome JAMA 305 2011 1210 1216
22. G. Ndrepepa, S. Braun, and J. Mehilli Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin Am Heart J 161 2011 68 75
23. M.C. Kontos, J.A. de Lemos, and F.S. Ou Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: an undertreated but high-risk patient group: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes NetworkGet With The Guidelines (NCDR ACTION-GWTG) Registry Am Heart J 160 2010 819 825
24. D.C. Corteville, D.F. Armstrong, and D.G. Montgomery Treatment and outcomes of first troponin-negative non-ST-segment elevation myocardial infarction Am J Cardiol 107 2011 24 29
25. W. Hochholzer, D.A. Morrow, and R.P. Giugliano Novel biomarkers in cardiovascular disease: update 2010 Am Heart J 160 2010 583 594
26. S. Agewall, E. Giannitsis, T. Jernberg, and H. Katus Troponin elevation in coronary vs. non-coronary disease Eur Heart J 32 2011 404 411
27. O.S. Dhillon, S.Q. Khan, and H.K. Narayan Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study J Am Coll Cardiol 56 2010 125 133
28. T.J. Wang Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction Circulation 123 2011 551 565
29. B.M. Scirica, D.A. Morrow, and C. Bode Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial Eur Heart J 31 2010 1993 2005
30. R.P. Giugliano, and E. Braunwald The year in non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 54 2009 1544 1555
31. B. Nazer, K.K. Ray, and S. Sloan Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome Eur Heart J 32 2011 1390 1397
32. K. Viswanathan, N. Kilcullen, and C. Morrell Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative J Am Coll Cardiol 55 2010 2590 2598
33. B.M. Scirica, M.S. Sabatine, and P. Jarolim Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial Eur Heart J 32 2011 697 705
34. F. Beygui, J. Silvain, and A. Pena Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates Am J Cardiol 106 2010 650 658
35. R. Glaser, W.F. Peacock, A.H. Wu, R. Muller, M. Mockel, and F.S. Apple Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study Am J Cardiol 107 2011 821 826
36. S.V. Raman, O.P. Simonetti, and M.W. Winner 3rd Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 55 2010 2480 2488
37. A.P. Lee, Q. Zhang, and G. Yip LV mechanical dyssynchrony in heart failure with preserved ejection fraction complicating acute coronary syndrome J Am Coll Cardiol Img 4 2011 348 357
38. F.A. Saab, P.G. Steg, and A. Avezum Can an elderly woman's heart be too strong? Increased mortality with high versus normal ejection fraction after an acute coronary syndrome. The Global Registry of Acute Coronary Events Am Heart J 160 2010 849 854
39. M.T. Lonnebakken, E.M. Staal, J.E. Nordrehaug, and E. Gerdts Usefulness of contrast echocardiography for predicting the severity of angiographic coronary disease in non-ST-elevation myocardial infarction Am J Cardiol 107 2011 1262 1267
40. G. Bedetti, L. Gargani, R. Sicari, M.L. Gianfaldoni, S. Molinaro, and E. Picano Comparison of prognostic value of echographic [corrected] risk score with the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry in Acute Coronary Events (GRACE) risk scores in acute coronary syndrome Am J Cardiol 106 2010 1709 1716
41. C.B. Granger, R.J. Goldberg, and O. Dabbous Predictors of hospital mortality in the global registry of acute coronary events Arch Intern Med 163 2003 2345 2353 (Pubitemid 37310196)
42. S.R. Mehta, J.P. Bassand, and S. Chrolavicius Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
43. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
44. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
45. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
46. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 (*)2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
47. L. Bonello, S. Armero, and O. Ait Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 (*)2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
48. G. Pare, S.R. Mehta, and S. Yusuf Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
49. H.J. Bouman, E. Schomig, and J.W. van Werkum Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
50. D. Sibbing, W. Koch, and S. Massberg No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
51. S.D. Wiviott, E.M. Antman, and E. Braunwald Prasugrel Circulation 122 2010 394 403
52. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
53. J.L. Mega, S.L. Close, and S.D. Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
54. A. Bellemain-Appaix, D. Brieger, and F. Beygui New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis J Am Coll Cardiol 56 2010 1542 1551
55. R.P. Giugliano, and E. Braunwald The year in non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 56 2010 2126 2138
56. G. Montalescot, L. Bolognese, and D. Dudek A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study Am Heart J 161 2011 65056.e1
57. C.T. Chin, M.T. Roe, and K.A. Fox Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 1622.e1
58. M.L. O'Donoghue, D.L. Bhatt, and S.D. Wiviott Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial Circulation 123 2011 1843 1853
59. S. Goto, H. Ogawa, M. Takeuchi, M.D. Flather, and D.L. Bhatt Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 31 2010 2601 2613
60. Merck Statement on Changes to Clinical Studies of Vorapaxar http://www.merck.com/newsroom/news-release-archive/research-and-development/ 2011-0113.html January 13, 2011 Accessed October 10, 2011
61. Follow-Up to the January 26, 2009, Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm November 17, 2009 Accessed October 10, 2011
62. T. Simon, P.G. Steg, and M. Gilard Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry Circulation 123 2011 474 482
63. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
64. M.Y. Chan, J.L. Sun, and T.Y. Wang Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY Am Heart J 160 2010 105664.e2
65. B. Elbarouni, O. Elmanfud, and R.T. Yan Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes Am Heart J 160 2010 420 427
66. M.B. Kadakia, N.R. Desai, and K.P. Alexander Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION RegistryGWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network RegistryGet With the Guidelines) J Am Coll Cardiol Intv 3 2010 1166 1177
67. R.P. Giugliano, R.R. Giraldez, and D.A. Morrow Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial Eur Heart J 31 2010 2103 2110
68. W. Hochholzer, S.D. Wiviott, and E.M. Antman Predictors of bleeding and time dependence of association of bleeding with mortality: insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With PrasugrelThrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) Circulation 123 2011 2681 2689
69. R. Mehran, S.J. Pocock, and E. Nikolsky A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566
70. R. Mathews, E.D. Peterson, and A.Y. Chen In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™ Am J Cardiol 107 2011 1136 1143
71. E. Abu-Assi, J.M. Gracia-Acuna, I. Ferreira-Gonzalez, C. Pena-Gil, P. Gayoso-Diz, and J.R. Gonzalez-Juanatey Evaluating the performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction Circulation 121 2010 2419 2426
72. R.D. Lopes, E.D. Peterson, and A.Y. Chen Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry J Am Coll Cardiol Intv 3 2010 669 677
73. P.G. Steg, S.S. Jolly, and S.R. Mehta Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial JAMA 304 2010 1339 1349
74. M.G. Cohen, D.A. Purdy, and J.S. Rossi First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention Circulation 122 2010 614 622
75. S. Schulz, J. Mehilli, and F.J. Neumann ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention Eur Heart J 31 2010 2482 2491
76. S.P. Marso, A.P. Amin, and J.A. House Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention JAMA 303 2010 2156 2164
77. S.S. Jolly, S. Yusuf, and J. Cairns Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial Lancet 377 2011 1409 1420
78. G.Y. Lip, K. Huber, and F. Andreotti Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summarya Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 31 2010 1311 1318
79. K.E. Airaksinen, H. Suurmunne, and P. Porela Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting Am J Cardiol 106 2010 175 179
80. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
81. C.M. Gibson, J.L. Mega, and P. Burton Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 81521.e6
82. D.G. Katritsis, G.C. Siontis, and A. Kastrati Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes Eur Heart J 32 2011 32 40
83. E.L. Hannan, Z. Samadashvili, and G. Walford Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-ST-segment elevation myocardial infarction Am J Cardiol 107 2011 1311 1318
84. C. Kaiser, S. Galatius, and P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319
85. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
86. S. Silber, S. Windecker, P. Vranckx, and P.W. Serruys Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
87. E. Braunwald, D.B. Mark, and R.H. Jones Unstable angina: diagnosis and management Clinical Practice Guideline No. 10 1994 Agency for Health Care Policy and Research, Public Health Service, National Heart, Lung, and Blood Institute Bethesda, MD
88. S.J. Park, Y.H. Kim, and D.W. Park Randomized trial of stents versus bypass surgery for left main coronary artery disease N Engl J Med 364 2011 1718 1727
89. M.C. Morice, P.W. Serruys, and A.P. Kappetein Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial Circulation 121 2010 2645 2653
90. E. Boudriot, H. Thiele, and T. Walther Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis J Am Coll Cardiol 57 2011 538 545
91. D.J. Cohen, B. Van Hout, and P.W. Serruys Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery N Engl J Med 364 2011 1016 1026
92. C. Melloni, B.R. Shah, and F.S. Ou Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry Am Heart J 160 2010 11219.e1
93. U. Javed, P.C. Deedwania, and D.L. Bhatt Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG) Am Heart J 160 2010 11306.e13
94. J. Armitage, L. Bowman, and K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
95. A.V. Khera, M.L. Wolfe, C.P. Cannon, J. Qin, and D.J. Rader On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study) Am J Cardiol 106 2010 451 456
96. C.P. Cannon, S. Shah, and H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
97. Launch of major international study to test new drug combination to cut cardiovascular disease http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/hps2- thrive-press-release May 31, 2006 Accessed October 10, 2011
98. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
99. K.A. Fox, K.F. Carruthers, and D.R. Dunbar Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study) Eur Heart J 31 2010 2755 2764
100. A.J. Bagnall, A.T. Yan, and R.T. Yan Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge Circ Cardiovasc Qual Outcomes 3 2010 530 537
101. A. Phrommintikul, S. Kuanprasert, W. Wongcharoen, R. Kanjanavanit, R. Chaiwarith, and A. Sukonthasarn Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome Eur Heart J 32 2011 1730 1735